Speaker: Jon A. Rowley, PhD, Founder & Chief Product Officer, RoosterBio

Developing allogeneic cell therapy products with scalable manufacturing takes years of time and costs millions of dollars, with lengthy process development campaigns extending timelines. This presentation will address development pain points and strategies for shortening those product/process development and clinical manufacturing timelines for hMSC-based products. It will also highlight standardized scale-up bioreactor processes for hMSCs to 50L, with comparability of quality parameters for streamlining product development efforts. Lastly, you will have the opportunity to learn about next generation approaches for hMSC-based extracellular vesicle and genetically engineered products.